- recruiting
Cognitive Performance, Sleep Disturbances and Fatigue in Multiple Sclerosis
This study looks at how sleep problems and tiredness (fatigue) affect people with Multiple Sclerosis (MS). Researchers want to understand if poor sleep makes MS-related fatigue and thinking problems worse, and how different types of MS are affected. They are also using AI to help analyse sleep data.
Germany - recruitingPHASE1
SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis
This study is investigating a new drug called ixazomib to see if it's safe and helpful for people with different types of multiple sclerosis (MS). We want to find out if it can reduce certain markers in the fluid around the brain and spinal cord.
United Kingdom - authorisedTherapeutic exploratory (Phase II)
A Phase 2a Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)
This study is looking at a new medicine called SUN-627 for people with certain types of Multiple Sclerosis (MS). Researchers want to see if it's safe, how the body uses it, and if it helps reduce inflammation in the brain over 16 weeks.
Finland - ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
Randomized, Single-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Melatonin Administration in Patients With Multiple Progressive Primary Sclerosis (MELATOMS)
This study is looking at how safe and effective melatonin, a natural sleep hormone, might be for people with a type of multiple sclerosis called Primary Progressive MS. Researchers want to see if it can slow down how the disease progresses.
Spain - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with primary progressive multiple sclerosis (PERSEUS)
This study is testing a new medicine, SAR442168, for people with Primary Progressive Multiple Sclerosis (PPMS). It's comparing the new medicine to a dummy pill to see if it can slow down the disease's progress and if it's safe to use.
Belgium · France · Austria